OPTHEA LTD (SP.ADR/8) (UKJ2) - Total Assets
Based on the latest financial reports, OPTHEA LTD (SP.ADR/8) (UKJ2) holds total assets worth €145.77 Million EUR (≈ $170.42 Million USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of OPTHEA LTD (SP.ADR/8) for net asset value and shareholders' equity analysis.
OPTHEA LTD (SP.ADR/8) - Total Assets Trend (2022–2025)
This chart illustrates how OPTHEA LTD (SP.ADR/8)'s total assets have evolved over time, based on quarterly financial data.
OPTHEA LTD (SP.ADR/8) - Asset Composition Analysis
Current Asset Composition (June 2025)
OPTHEA LTD (SP.ADR/8)'s total assets of €145.77 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 85.3% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how OPTHEA LTD (SP.ADR/8)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see UKJ2 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: OPTHEA LTD (SP.ADR/8)'s current assets represent 100.0% of total assets in 2025, an increase from 99.8% in 2022.
- Cash Position: Cash and equivalents constituted 85.3% of total assets in 2025, up from 74.3% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
OPTHEA LTD (SP.ADR/8) Competitors by Total Assets
Key competitors of OPTHEA LTD (SP.ADR/8) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.21 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Crispr Therapeutics AG
NASDAQ:CRSP
|
USA | $2.73 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €2.00 Billion |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
OPTHEA LTD (SP.ADR/8) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.57 | 2.94 | - |
| Quick Ratio | 1.57 | 2.94 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | €52.38 Million | €124.14 Million | - |
OPTHEA LTD (SP.ADR/8) - Advanced Valuation Insights
This section examines the relationship between OPTHEA LTD (SP.ADR/8)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.38 |
| Latest Market Cap to Assets Ratio | 9.03 |
| Asset Growth Rate (YoY) | -69.9% |
| Total Assets | €56.80 Million |
| Market Capitalization | $512.99 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values OPTHEA LTD (SP.ADR/8)'s assets at a significant premium (9.03x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: OPTHEA LTD (SP.ADR/8)'s assets decreased by 69.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for OPTHEA LTD (SP.ADR/8) (2022–2025)
The table below shows the annual total assets of OPTHEA LTD (SP.ADR/8) from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | €56.80 Million ≈ $66.40 Million |
-69.91% |
| 2024-06-30 | €188.79 Million ≈ $220.72 Million |
+91.39% |
| 2023-06-30 | €98.64 Million ≈ $115.32 Million |
+64.27% |
| 2022-06-30 | €60.05 Million ≈ $70.20 Million |
-- |
About OPTHEA LTD (SP.ADR/8)
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME).… Read more